Detalles de la búsqueda
1.
Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial.
Ann Oncol
; 28(8): 1817-1824, 2017 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28459938
2.
Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial.
Ann Oncol
; 28(8): 1832-1835, 2017 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28525534
3.
A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial.
Br J Cancer
; 108(4): 866-72, 2013 Mar 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-23299526
4.
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials.
Br J Cancer
; 107(8): 1257-67, 2012 Oct 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-23047592
5.
Accuracy of unidimensional and volumetric ultrasound measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patients.
Breast Cancer Res Treat
; 127(2): 459-69, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21437610
Resultados
1 -
5
de 5
1
Próxima >
>>